Retatrutide 40 is an investigational injectable medication being studied for obesity and type 2 diabetes. It is known as a triple agonist because it activates three hormone receptors: GLP-1, GIP, and glucagon. This combination helps reduce appetite, increase energy expenditure, improve insulin sensitivity, and enhance fat loss. Compared with current GLP-1–based drugs, retatrutide has shown greater weight-loss potential in early clinical trials. It is administered as a once-weekly injection with gradual dose escalation. Common side effects are similar to other incretin drugs and include nausea, vomiting, and gastrointestinal discomfort. As of now, retatrutide is still under clinical development and not yet approved Reconstituted with 100 units (1 mL) Bacteriostatic Water, using a 1 mL Insulin Syringe (100 units) for dosing.
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes. With an extended half-life of approximately 6 days, this peptide enables convenient once-weekly subcutaneous dosing with a gradual titration protocol to optimize tolerability.
Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration for convenient weekly dosing.
DOSE weekly range: 2–12 mg once weekly (gradual escalation over 12+ weeks).